Skip to main content

Table 3 Clinicopathological characteristics of patients included in the validation cohort

From: Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Feature

Nr (%)

CAPS

Q1

Median

Q4

P-value

Age, years

 Median

63

 Range

32–87

 <50

21 (27%)

9.6

14.6

22.3

 ≥50

58 (73%)

18.7

21

38.4

0.0049

Tumor size

45 (57%)

18.2

25.5

36.1

 T1

 T2–3

34 (43%)

11.5

20.1

31.2

0.15

S-phase

 <10%

50 (78%)

16.5

25.5

33

 ≥10%

14 (22%)

8.5

19.7

42.9

0.29

 Missing

15

Lymph-node status

 Node-negative

42 (56%)

17.4

24.8

38.9

 Node positive

33 (44%)

12.6

24.3

32.0

0.33

 Missing

4

PgR (fmol/μg DNA)

     

 Neg (≤0.09)

23 (29%)

14.8

30.5

38.9

 Pos (>0.09)

56 (71%)

14.6

24.3

29.7

0.58

  1. All patients were ER positive (Average ER = 4.4 fmol/μg DNA) and received adjuvant tamoxifen as the only systemic adjuvant treatment. CAPS protein levels were determined by ELISA (n = 79). Mann-Whitney’s test for significance. Abbreviation: PgR, progesterone receptor.
Back to article page

Clinical Proteomics

ISSN: 1559-0275